Imetrikus Inc.

As Chief Medical Officer, Dr. Harvey Colten oversees the clinical direction of the company and chairs the iMetrikus Medical Advisory Board. In addition to serving as iMetrikus' CMO, Dr. Colten is also Vice President and Senior Associate Dean for Academic Affairs at Columbia University.

As Senior Vice President of Marketing, Robert Murphy is responsible for setting the strategic marketing and product direction for the company, managing the development of market differentiating products, marketing communications planning and implementation, maintaining the company's corporate image and brand awareness, sales support and business development and campaign management to support the company's business plan. Formerly owner and principal of Team 2 Marketing, Murphy has worked with organizations ranging from start-ups to Fortune 50 companies. He has over twenty years of hands-on marketing management experience in the health care, retail and service industries. Prior to launching Team 2, Murphy's career in health care included management team assignments at SHPS/CareWise and McKesson/Access Health where he led marketing, product development and product management activities for these personal health management companies. While Vice President at San Francisco advertising agency BBDO/Jamison, Cawdrey, Benjamin, he was accountable for directing account and creative services for various clients, including Pizza Hut, Jiffy Lube, Hyatt Hotels, and PacTel. He earned his Bachelor of Business Administration degree at the University of Massachusetts/Amherst.

Dr. Rutter is Chairman and CEO of Synergenics, LLC, Chairman Emeritus of Chiron Corporation and Herzstein Professor of Biochemistry Emeritus at the University of California, San Francisco (UCSF) where he played a key role in developing UCSF in a major scientific contributor. Dr. Rutter previously served as a founder and Chairman of Chiron Corporation and member of the Board of Director of Ciba-Greigy/Novartis. He was instrumental in building Chiron into a global biotech power house. In his academic career, Dr. Rutter was chairman of the Department of Biochemistry and Biophysics at the University of California, San Francisco. The department played a key role in developing recombinant DNA technology, genetic engineering and information of biotech companies to develop and exploit technology. During the early days in Chiron, he was concurrently the Director of the Hormone Research Institute at UCSF. Dr. Rutter and colleagues have published more than 380 scientific articles and holds more than 25 patents. His lab made several early contributions in biotechnology, including the first cloning of the insulin gene; the development of a process for making a vaccine against hepatitis B virus, the first vaccine based on recombinant DNA methodology. Dr. Rutter was elected to the U.S. National Academic of Sciences and American Academy of Arts and Sciences more than two decades ago. Under Dr. Rutter's leadership, Chiron placed a major emphasis on the detection and prevention of infectious diseases. In collaboration with Merck, Chiron developed a process for manufacturing the Hepatitis B vaccine from yeast that is used by Merck and all the major manufacturers of this vaccine. Dr. Rutter's commitment to funding research on important infectious diseases led to the first sequencing of the HIV genome in 1984, and the discovery, sequencing and cloning of the hepatitis C virus in 1987, two of Chiron's most enduring achievements. These discoveries have led to sensitive diagnostic tests, for example, used in screening for contaminated blood worldwide, and to new technologies and development of vaccines and therapeutic drugs against these viruses In addition to work on Infectious Disease, Chiron under Dr. Rutter's direction, was involved in several other major therapeutic projects against cancer and metabolic disease. For example, Chiron, with Nordisk (now Novo-Nordisk), developed a process for manufacturing human insulin via production of the natural intermediate, proinsulin (different from the process developed by Genentech). This process is now used worldwide by all manufacturers of human insulin. In 1999, Dr. Rutter founded Synergenics, LLC, which operates a consortium of commonly-owned but independent biotech companies offering an innovative and cost-effective approach to start-ups in the life sciences industry. Synergenics provides member companies with financial support, shared laboratory facilities and experienced management and administrative services, creating true economies of scale. In addition, the Synergenics concept provides an open and collaborative environment among member companies that allows a free exchange of ideas and technology, while protecting each company's defined proprietary domains. Synergenics Portiflio Companies

John W. Larson has served as a member of our Board of Directors since January 1996. Mr. Larson is currently a partner at the law firm of Morgan, Lewis & Bockius LLP. Mr. Larson served as partner at the law firm of Brobeck, Phleger & Harrison LLP (Brobeck) from 1969 until retiring in January 2003, except for the period from July 1971 to September 1973 when he was in government service as Assistant Secretary of the United States Department of the Interior and Counselor to George P. Shultz, Chairman of the Cost of Living Council. From 1988 until March 1996, Mr. Larson was Chief Executive Officer of Brobeck. Mr. Larson serves on the board of the Needham Funds and on the boards of several privately held companies. Mr. Larson holds an L.L.B. and a B.A., with distinction, in economics, from Stanford University.

Dr. Linda Neuhauser is a Clinical Professor in the Division of Community Health and Human Development at the University of California, Berkeley, School of Public Health. Her work focuses on the science and techniques to translate research findings to successful action for large-scale societal benefits. She has a particular emphasis on Internet and other mass communication strategies to improve people's health. She is Co-Principal Investigator of Health Research for Action, a center at the School of Public Health that develops multi-media, multi-lingual health communication for households in the U.S. and overseas. Dr. Neuhauser is a member of the US Food and Drug Administration's Risk Communication Advisory Committee and has served on many federal task forces related to communication for the public. She was formerly a Health Officer in the US Department of State in West and Central Africa.